4D Molecular Therapeutics (NASDAQ:FDMT) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a research report sent to investors on Monday morning, MarketBeat Ratings reports. They currently have a $36.00 target price on the stock.

A number of other analysts have also weighed in on the company. The Goldman Sachs Group set a $33.00 target price on 4D Molecular Therapeutics in a research note on Friday, May 8th. Wall Street Zen lowered shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Friday. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $21.00 price target (down from $40.00) on shares of 4D Molecular Therapeutics in a research note on Monday, March 30th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, 4D Molecular Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $29.88.

4D Molecular Therapeutics Trading Up 0.9%

Shares of NASDAQ:FDMT opened at $11.09 on Monday. The company has a market capitalization of $579.79 million, a price-to-earnings ratio of -4.32 and a beta of 2.70. The firm’s 50-day moving average is $10.37 and its 200 day moving average is $9.48. 4D Molecular Therapeutics has a 12 month low of $4.14 and a 12 month high of $14.00.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%.The business had revenue of $3.05 million during the quarter, compared to analysts’ expectations of $2.59 million. As a group, equities analysts forecast that 4D Molecular Therapeutics will post -4.14 EPS for the current fiscal year.

Insiders Place Their Bets

In other 4D Molecular Therapeutics news, insider Scott Bizily sold 9,810 shares of 4D Molecular Therapeutics stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total transaction of $117,720.00. Following the completion of the sale, the insider directly owned 8,617 shares of the company’s stock, valued at $103,404. The trade was a 53.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider David Kirn sold 15,725 shares of the stock in a transaction on Friday, July 10th. The stock was sold at an average price of $12.03, for a total value of $189,171.75. Following the transaction, the insider directly owned 884,152 shares in the company, valued at $10,636,348.56. The trade was a 1.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 184,811 shares of company stock valued at $2,075,906. 7.90% of the stock is currently owned by corporate insiders.

Institutional Trading of 4D Molecular Therapeutics

A number of hedge funds have recently added to or reduced their stakes in FDMT. Wexford Capital LP purchased a new position in 4D Molecular Therapeutics during the 3rd quarter valued at about $41,000. Daiwa Securities Group Inc. lifted its holdings in 4D Molecular Therapeutics by 3,362.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock worth $48,000 after buying an additional 6,186 shares during the period. Susquehanna Portfolio Strategies LLC bought a new stake in 4D Molecular Therapeutics during the 4th quarter valued at $77,000. Martingale Asset Management L P boosted its position in 4D Molecular Therapeutics by 12.4% during the 4th quarter. Martingale Asset Management L P now owns 11,775 shares of the company’s stock valued at $88,000 after acquiring an additional 1,303 shares in the last quarter. Finally, Gabelli Funds LLC purchased a new position in shares of 4D Molecular Therapeutics in the 4th quarter valued at $90,000. 99.27% of the stock is owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.